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effects, only 3,424 prescriptions were reimbursed. Reimbursement per prescription 
varied by state; in 2001, the national average was $107. CONCLUSIONS: Despite an 
obesity epidemic, very few states reimbursed pharmacies for weight-loss medica-
tions, including orlistat. Understanding the different decisions that the states made 
with respect to weight-loss pharmacotherapy is a goal for future research.
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OBJECTIVES: An estimated 100 million adults suffer from chronic pain in the US. 
The total cost of pain ranges from $560 to $635 billion in 2010, exceeding that of 
heart disease ($309 billion), cancer ($243 billion), and diabetes ($188 billion). The 2011 
IOM report on pain states that effective pain management is “a moral imperative” 
for health care providers. Many pharmaceutical options are available to prescribers, 
most notably prescription opioids. Prescription opioids are analgesics which can 
be effective for the treatment of pain when monitored appropriately. Hydrocodone 
combination products are among the most commonly prescribed opioids in the 
US. The objective of this study was to perform a comprehensive literature review 
of the use and impact of hydrocodone in the US. METHODS: A comprehensive 
literature review was conducted regarding the use and impact of hydrocodone in 
the US. RESULTS: The US consumed 80% of the global supply of opioids and 99% 
of the global hydrocodone supply. From 1997 to 2007, hydrocodone use increased 
280%. Due to their potential for harm and abuse, hydrocodone combination prod-
ucts were recently rescheduled from Schedule III to Schedule II by the U.S. Food 
and Drug Administration (FDA). Single entity hydrocodone extended release was 
recently approved by the FDA and has been met with much controversy due to its 
potential for abuse. CONCLUSIONS: Hydrocodone use is highly prevalent in the 
US. Long-term use of hydrocodone and single entity hydrocodone use need to be 
actively monitored for appropriateness. Future studies should assess the impact 
of rescheduling.
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OBJECTIVES: Chronic or long-term pain disturbs numerous lives, which is one of the 
most prevalent reasons for doctor visits and reduces people’s quality of life. A com-
mon treatment for long-term non-cancer pain (CNCP) is long-term opioid therapy. 
However, the effectiveness of opioids for CNCP is still controversy and associated 
medical expenditure is vague. We investigated the impact of opioid treatment on 
the total medical expenditures for U.S. general population. METHODS: We used 
the 2011 Medical Expenditure Panel Survey, a nationally representative survey for 
health care use, expenditures and health insurance coverage of the U.S. civilian non-
institutionalized population. After excluding individuals with the priority condition 
of cancer and current diagnosis of cancer, we used response to the SF-12 question-
naire and ICD codes to identify chronic pain conditions. The final sample includes 
11,858 individuals with 355 receiving opioid treatments. We conducted bivariate 
statistical analysis to compare demographic characteristics, clinical conditions and 
total expenditures for CNCP patients’ between on- and off-opioid treatment groups. 
Using a multivariate generalized linear model (GLM), we estimated the impact of 
opioid treatment on medical care expenditures for CNCP patients, after adjusting 
for covariates. RESULTS: The bivariate analysis results show statistical significant 
differences in the use of opioid treatments associated with race/ethnicity, education 
level, smoking status, physical activity, and health status. The unadjusted mean 
total annual medical expenditures were $29,914 for opioid users and $8,564 for 
non-opioid users. The GLM regression results show the opioid treatment is associ-
ated with $3,419 to $9,120 in additional medical expenditure, after adjusting covari-
ates. CONCLUSIONS: Appropriate management for CNCP is critical to improve their 
perceived health and wellbeing and to decrease medical expenditures. However, 
due to the cross-sectional design, there might be some higher spending for opioid 
users results from unobserved patient severity, as well as no treatment outcome 
measures, which needs further study.
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OBJECTIVES: High cost biologic treatments for diseases such as plaque psoriasis, 
raise growing concerns over the increasing cost to the health care systems that 
are funding these treatments. Administrative databases can generate important 
information about the way these drugs are prescribed in a “real world” setting. The 
objectives of this analysis were to determine the initial dosing and identify dose 
escalation patterns for biologics in the treatment of psoriasis in Canada. METHODS: 
A sample of data from patients covered by the public (Quebec and Ontario) and pri-
vate drug plans in Canada, who received a biologic between January 2010 and August 
2012 for at least 12 months, were retrieved (IMS Brogan, IMS Longitudinal Claims 
Dataset, Jan 2010 - Aug 2013, reported Nov 2013). A specific algorithm was developed 
based on prescriber information and concomitant medications to capture claims 
associated to psoriasis. Dosing analysis was performed for four biologics approved 
for psoriasis in Canada: adalimumab, etanercept, infliximab and ustekinumab. Dose 
escalation was defined as a 20% dose increase above the previous dose, excluding 
induction. RESULTS: A total of 4,510 patients were identified and met inclusion 
criteria. The average first year dose was higher than years 2 and 3, consistent with 
OBJECTIVES: Although opioids play a central role in the treatment, and palliation 
of many medical conditions, there is a large and growing problem of abuse nation-
ally and in South Carolina particularly. According to the 2009 National Survey on 
Drug Use and Health, more than 5 million Americans abused prescription opioid 
painkillers in January 2011. Reports show an increase in cases of doctor shopping, 
prescription forgery, illicit prescribing and dispensing, and other diversion activi-
ties. We determine patterns of opioid prescribing in South Carolina through an 
epidemiologic analysis and geo-spatial mapping of South Carolina prescription 
data for 2010-2011. METHODS: Using de-identified data from the South Carolina 
Reporting and Identification Prescription Tracking System (SCRIPTS), we conducted 
a state-wide epidemiological analysis of patient and prescriber opioid prescribing 
patterns including distributions of number of prescriptions, number of prescribers 
and of pharmacies used by each patient. Additionally, we conducted County- and Zip 
Code-level analyses of opioid prescribing patterns. RESULTS: Prescriber deciles were 
created representing 10% groupings of prescribers based on controlled substances 
(CS) II – IV prescription volume. The top 10% of SC prescribers wrote more than 60% 
(N= 2,158,574) of the total CS II – IV prescriptions in 2010, and 58% of total opioid 
prescriptions. The top pharmacy decile dispensed about 44% of total prescriptions 
and about 37% of opioid prescriptions. Five Zip Codes had the highest percent of 
opioid prescriptions out of total prescriptions (Charleston, Richland, Greenville, 
Barnwell and Aiken). In 2010 counties with the highest percent of prescriptions 
(> 61%) were Greenville, Richland, Barnwell and Charleston, whereas in 2011 the 
counties with the highest percent of prescriptions were Greenville, Chester, Richland 
and Charleston. CONCLUSIONS: Our findings indicate a relatively small percentage 
of providers, concentrated in a few counties, account for most opioid prescriptions. 
This group represents a potential target for physician education and engagement 
in handling pain management and appropriate use of opioids.
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OBJECTIVES: Many chronic users of immediate-release opioids (IROs) initiating 
treatment with extended-release opioids (EROs) are steered towards generic options, 
even if switching molecules is required. Switching may introduce uncertainty for 
patients regarding dosing, titration and efficacy. This study assessed treatment 
patterns among patients chronically-treated with IR oxycodone who initiate ERO 
treatment, and describes differences between patients initiating treatment on 
the same molecule and those who switch molecules. METHODS: Commercially-
insured patients aged < 65 were selected from de-identified OptumHealth Reporting 
and Insights claims data, 2011-2014. Chronic IR oxycodone users were defined as 
patients with ≥ 2 continuous prescriptions and ≥ 60 days supply leading up to initia-
tion of ERO treatment (index). Patients were excluded if they had claims for EROs 
during a 6-month baseline period or possible opioid replacement therapy (metha-
done/buprenorphine) during the 6-month follow-up period, and were required to 
be continuous users of opioids throughout follow-up. The sample was stratified 
based on whether ER therapy was initiated on the same molecule (ER oxycodone) 
or different molecules. Treatment patterns and pill count were assessed for both 
cohorts. RESULTS: During baseline, 2,318 chronic IR oxycodone users initiating 
EROs were identified, with 933 (40%) initiating ER oxycodone and the remainder 
switching molecules. Same-molecule patients were more likely to continuously 
use index therapy (41.9% vs. 33.6%), and less likely to switch to a different ERO 
(12.3% vs. 26.0%). Among different-molecule patients switching EROs, nearly half 
switched to ER oxycodone. Concomitant use of IR oxycodone was observed in both 
groups, but continuous index ERO users in the same-molecule cohort saw a greater 
decline in IR pill count compared with the different-molecule cohort (-173.3 vs. 
-105.9). CONCLUSIONS: Chronic IR oxycodone patients initiating EROs on the same 
molecule were more likely to remain on index treatment, and those remaining on 
treatment experienced a greater decline in IR oxycodone pill count.
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OBJECTIVES: More than one third of adults in the U.S. are considered obese (body 
mass index ≥ 30kg/m2). Because of their relatively low socioeconomic status, the 
Medicaid population is disproportionately affected by obesity. The objective was to 
compare the utilization of and spending on anti-obesity medication, specifically 
orlistat (amphetamine-based weight-loss drugs were highly restricted by Medicaid 
because of their potential for abuse), by state Medicaid programs from 1999-2013. 
Orlistat, approved by the FDA in April 1999, is a gastric and pancreatic lipase inhibi-
tor that reduces dietary fat absorption. METHODS: Using the individual state files 
for Medicaid outpatient drug utilization maintained by the Centers for Medicare 
and Medicaid Services, quarterly utilization and (pre-rebate) expenditure data 
from 1999-2013 were extracted for all branded and generic orlistat prescriptions 
for Medicaid beneficiaries. Descriptive statistics were computed. RESULTS: In 1999, 
North Carolina reimbursed 5,242 prescriptions; Louisiana 3,712 prescriptions; and 
Wisconsin 1,460. Subsequently, several other states, such as California, Connecticut, 
Kentucky, Minnesota, New Jersey, and Pennsylvania came on board with a fairly large 
number of prescriptions reimbursed (6,041 in California in 2003). In other states, like 
Ohio and New York, no orlistat prescriptions were reimbursed until the last years of 
the study, most likely representing a policy shift. In 2001,when Medicaid utilization 
was at its peak, a total of 87,811 prescriptions were reimbursed across the country. 
By 2013, due to several factors including an over-the-counter version of orlistat 
approved by the FDA in 2010 and a loss in popularity due to gastrointestinal side 
